Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions. by Avril, Tony et al.
Distinct effects of human glioblastoma
immunoregulatory molecules programmed cell death
ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase
(IDO) on tumour-specific T cell functions.
Tony Avril, Ste´phan Saikali, Elodie Vaule´on, Anne Jary, Abderrahmane
Hamlat, Marie De Tayrac, Jean Mosser, Ve´ronique Quillien
To cite this version:
Tony Avril, Ste´phan Saikali, Elodie Vaule´on, Anne Jary, Abderrahmane Hamlat, et al.. Distinct
effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1
(PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions.. Journal
of Neuroimmunology, Elsevier, 2010, 225 (1-2), pp.22-33. <10.1016/j.jneuroim.2010.04.003>.
<inserm-00486777>
HAL Id: inserm-00486777
http://www.hal.inserm.fr/inserm-00486777
Submitted on 26 May 2010
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

Distinct effects of human glioblastoma immunoregulatory molecules programmed cell 
death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T 
cell functions. 
 
Tony AVRIL1, Stéphan SAIKALI2, Elodie VAULEON1,3, Anne JARY1, Abderrahmane 
HAMLAT4, Marie DE TAYRAC3, Jean MOSSER3, Véronique QUILLIEN1,3 
 
Authors’ affiliation: 
1 Département de Biologie, Centre Eugène Marquis, Rennes, France 
2 Département d’anatomopathologie, CHU Pontchaillou, Rennes, France 
3 UMR 6061 CNRS, Université de Rennes 1, IFR 140, Rennes, France 
4 Département de Neurochirurgie, CHU Ponchaillou, Rennes, France 
 
Address for reprint requests:  
Tony AVRIL, Département de Biologie, Centre Eugène Marquis, Rue de la bataille Flandres 
Dunkerque, CS44229, 35042 Rennes cedex, FRANCE. Phone: 33-299-253-190. Email: 
t.avril@rennes.fnclcc.fr. 
 
 
Grant support:  
This work was supported by the “Ligue Contre le Cancer” Committee of Ille-et-Villaine and 
Maine-et-Loire, as well as the Institut National du Cancer (the ‘From the core to the margin’ 
glioma project), Région Bretagne (GIS Thérapie cellulaire, CPER 2000-2006), and the 
foundation “Aidez la recherche”. 
 
ABSTRACT 
 
  Immunotherapy is a promising new treatment for patients suffering from glioma, in 
particular glioblastoma multiforme (GBM). However, tumour cells use different mechanisms 
to escape the immune responses induced by the treatment. As many other tumours, gliomas 
express or secrete several immunosuppressive molecules that regulate immune cell functions. 
In this study, we first analysed FasL, HLA-G, IDO, PDL-1 and TGF-β1, -β2 and -β3 
expression by transcriptomic microarray analysis in a series of 20 GBM samples and found 
respectively 15%, 60%, 85%, 30%, 70%, 80% and 35% of positive specimens. mRNA 
expression was then confirmed in 10 GBM primary cell lines and 2 immortalised cell lines 
U251 and U87MG. Furthermore, the protein expression of PDL-1, IDO activity and TGF-β2 
secretion were found on most of the untreated GBM primary cell lines. Remarkably, treatment 
with IFN-γ increased the PDL-1 cell surface expression and the IDO activity, but reduced the 
TGF-β2 secretion of GBM cell lines. We finally analysed the immunosuppressive effects of 
IDO, PDL-1 and TGF-β1-3 by measuring IFN-γ production and cell cytotoxicity activity of 
tumour antigen-specific T cells. PDL-1 partially affected the IFN-γ production of antigen-
specific T cells in response to GBM primary cell lines, and IDO inhibited lymphocyte 
proliferation induced by lectins. None of these molecules directly affected the T cell 
cytotoxicity function. Due to the functional role of PDL-1 and IDO molecules expressed by 
GBM cells, one could expect that blocking these molecules in the immunotherapy strategies 
would reinforce the efficiency of these treatments of GBM patients. 
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1. INTRODUCTION 
 
  Glioblastoma multiforme, the most common primary brain tumour in adults, is an attractive 
target for novel therapies regarding its poor prognosis with standard treatment including total 
surgical resection, radiotherapy and adjuvant chemotherapy (Stupp et al., 2005). Indeed, 
despite intensive investigations for novel drugs, less than a third of patients survive more than 
two years (Stupp et al., 2009). Recurrence of GBM occurs most often within few months due 
to the re-growth of remaining tumour cells that are resistant to both radiotherapeutic and 
chemotherapeutic agents. 
  Cellular immunotherapy in gliomas, one of the promising new therapies, has shown 
convincing results in terms of induction of anti-tumour immune responses and prolonged 
survival compared with control groups receiving conventional chemotherapy and radiotherapy 
(Yamanaka, 2008). In particular, patients treated with dendritic cell vaccinations have 
demonstrated systemic antigen-specific cytotoxicity and intra-tumour infiltration of cytotoxic 
T cells (Yamanaka et al., 2003), (Kikuchi et al., 2004), (Yu et al., 2004), (Yamanaka et al., 
2005). Liau et al. recently reported that T cell infiltration within the tumour was inversely 
correlated with the secretion of Transforming Growth Factor-beta 2 (TGF-β2) by the glioma 
cells (Liau et al., 2005), highlighting the impact of the immunosuppressive properties of the 
tumour on the clinical efficiency of the treatment.  
  Local and systemic immune suppression has been involved in glioma progression (Weller 
and Fontana, 1995), (Walker et al., 2002). TGF-β2, originally defined as the glioblastoma 
cell-derived T-cell suppressor factor, is a molecule that suppresses T cell growth and inhibits 
T cell activation and differentiation into effector cells (Gorelik and Flavell, 2002). Several 
other intra-cellular, membrane and soluble molecules such as FasL, HLA-G, PDL-1 (for 
Programmed cell Death Ligand-1, CD274), IDO (for Indoleamine2,3-DiOxygenase) and 
TGF-β1-3 have been described as taking part in this phenomenon. The Fas ligand (FasL, 
CD178), which is a member of the TNF family, induces apoptosis in Fas (CD95)-expressing 
cells (Nagata and Golstein, 1995). Although FasL is expressed by immune cells as a cytotoxic 
molecule, it is also found on the surface of different types of cancer cells (Walker et al., 
1997). FasL is expressed in human malignant glioma cells (Gratas et al., 1997). In addition, 
FasL expressed on glioma cell lines is active and induces the death of sensitive target cells 
such as Fas-transfected P815 cells (Saas et al., 1997), JURKAT T cell line (Weller et al., 
1997) and T cell lines derived from infiltrating T lymphocytes from astrocytoma (Walker et 
al., 1997). HLA-G is a non-classical MHC class I molecule mainly expressed on placenta by 
the trophoblastic cells (Kovats et al., 1990). Although HLA-G mRNA expression has also 
been found in tumour cells such as melanoma and leukaemia cells, its protein expression is 
still controversial because of the heterogeneity of the results observed in the different studies 
(Bainbridge et al., 2001), (Chang and Ferrone, 2003). HLA-G can interact directly or 
indirectly (via the HLA-E molecule) with inhibitory receptors expressed on cytotoxic 
lymphocytes, which induces the abrogation of effector cell activation (Carosella et al., 2008). 
Wiendl et al. describe the expression of HLA-G in brain tumour tissues and glioma cell lines, 
and demonstrate that cytotoxicity, proliferation and T cell priming of alloreactive PBMC are 
inhibited by HLA-G (Wiendl et al., 2002). PDL-1 belongs to the B7 family, and is expressed 
on antigen presenting cells (Greenwald et al, 2005). Engagement of its receptor PD-1 inhibits 
T cell functions such as proliferation, cytokine production and cytotoxicity, and promotes 
apoptosis (Freeman et al., 2000), (Dong et al., 2002). PDL-1 has been observed on glioma and 
astrocytoma cell lines, and reduces IFN-γ production of allogenic T cells (Wintterle et al., 
2003), (Wilmotte et al., 2005). Finally, IDO is an intracellular enzyme that degrades 
tryptophan along the kynurenin pathway. IDO activity is essential in mouse placenta for 
preventing the rejection of allogenic fetuses (Munn et al., 1998). Its activity suppresses T cell 
activation and proliferation (Munn et al., 1999). IDO expression has also been described in 
cancer of different origins (Munn and Mellor, 2007), (Katz et al., 2008), including gliomas 
(Uyttenhove et al., 2003) and malignant glioma cell lines (Grant and Kapoor, 2003), 
(Miyazaki et al., 2009), in which both IDO expression and activity have recently been 
reported. To our knowledge, the effect of glioma cell IDO activity on T cell functions has not 
been investigated. 
  While the expression of FasL, HLA-G, PDL-1, IDO and TGF-β1-3 molecules has been 
reported in glioma cells, their role in modulating GBM-specific T cell effector functions is not 
fully understood. This is particularly relevant with regard to cellular immunotherapy, whereby 
tumour-specific T cells would be generated to specifically kill GBM cells. In this study, we 
first describe the expression pattern of FasL, HLA-G, PDL-1, IDO and TGF-β1-3 in a series 
of 20 GBM specimens using data derived from our previous transcriptomic analysis (de 
Tayrac et al., 2009). The mRNA expression of these molecules is then analysed in 10 GBM 
primary cell lines, as well as the immortalised cell lines U251 and U87MG. We then focus on 
the immunosuppressive effects of PDL-1, IDO and TGF-β1-3 on GBM-specific CD8+ T cell 
effector functions, i.e. IFN-γ secretion and cell cytotoxicity in response to GBM primary cell 
lines. We show that none of these molecules have a direct effect on cell cytotoxicity 
functions, but we provide evidence that PDL-1 affects GBM-specific CD8+ T cell IFN-γ 
secretion in response to the tumour, and that GBM expresses functional IDO that inhibits the 
lectin-induced proliferation of lymphocytes. 
 
2. MATERIALS AND METHODS 
 
Reagents and antibodies. 
  All reagents not specified below were purchased from Sigma-Aldrich (St Quentin Fallavier, 
France). Antibodies against CD3, CD8, HLA-ABC and PDL-1 were obtained from BD 
Biosciences (Le Pont de Claix, France); Melan-A/HLA-A2 tetramers from Beckman Coulter 
(Marseille, France); anti-EGFRvIII antibody from Skybio (Bedfordshire, United Kingdom); 
anti-IDO antibody from Millipore (St Quentin Fallavier, France); anti-IL13Rα2 antibody from 
Diaclone (Besançon, France); anti-gp100 and anti-vimentin antibodies from DakoCytomation 
(Trappes, France); anti-HLA-G from Abcam (Paris, France); purified anti-PDL-1 from 
Clinisciences (Montrouge, France). 
 
Tumour samples and cell culture. 
  GBM samples were obtained after informed consent of patients treated at the department of 
neurosurgery (Rennes University Hospital) in accordance with the local ethical committee. 
Tumours included in this study were diagnosed histologically as GBM or astrocytoma grade 
IV according to the WHO criteria.  
  GBM primary cell lines were obtained from GBM samples. After mechanical dissociation of 
tumour tissues samples, cells were grown in Dulbecco’s Modification of Eagle’s Medium 
(DMEM, Lonza, Verviers, Belgium) supplemented with 10% fetal calf serum (FCS) (Lonza) 
for 24 hours at 37°C in a humid atmosphere of 5% CO2. Unattached cells were then removed 
the day after. When confluence was achieved, cells were trypsinised, washed in PBS and used 
between the 10th to 20th passage for the experiments. Human trophoblastic cell line JEG-3 and 
glioblastoma cell lines U251 and U87MG were kindly provided by L. Amiot (Rennes, 
France), V. Catros (Rennes) and A. Clavreul (Angers, France), respectively. All the 
immortalised cell lines were cultured in DMEM 10% FCS. 
 
mRNA preparation, Reverse Transcriptase (RT)-PCR and electrophoresis. 
  Total RNA extraction was performed using the Rneasy Mini kit from Qiagen (Courtaboeuf, 
France) according to the manufacturer’s recommendations. RNA concentrations were 
determined by optical density at 260 nm, and RNA samples were stored at -80°C until 
analysis. cDNA was prepared from 2 µg purified RNA (First Strand cDNA Synthesis kit, 
Amersham Biosciences, Saclay, France) and 10-fold diluted before use. cDNA were 
amplified with a Taq polymerase and specific primers for human β-actin, FasL, HLA-G, IDO, 
PDL-1 and TGF-β1-3 (MWG Biotech, Ebersberg, Germany) (Table 1). PCR was performed 
with a thermal cycler (RoboCycler Gradient 40, Stratagene, Amsterdam, Netherlands). After 
amplification, 25 µl from each PCR product were electrophoresed on 2% agarose gel, and an 
amplified band was detected by ethidium bromide staining. The 100 bp DNA ladder was used 
as molecular weight marker (Invitrogen, Cergy Pontoise, France). 
 
Quantitative reverse transcriptase (Q)-PCR. 
  Total RNA extraction was performed as described above. cDNA was prepared from 0.5 µg 
purified RNA (High capacity cDNA reverse transcription kit, Applied Biosystems, Applied 
Biosystems, Courtaboeuf, France) and 25-fold diluted before use. Real time-PCR was 
performed with a spectrofluorometric thermal cycler (7900 HT Fast Real-Time PCR System, 
Applied Biosystems) following the manufacturer’s recommendations, except for the final 
PCR volume that was decreased to 12 µl. IDO and PDL-1 primers and probes were purchased 
from Applied Biosystems (TaqMan assays-on-demand). Each data point was run in triplicate. 
To normalize the data, GAPDH was chosen as an endogenous control and tested in separate 
wells. The comparative Ct method was used to determine relative gene copy numbers. Firstly, 
the ΔCt was taken as equal to Ct of the antigen of interest minus Ct of GAPDH. The relative 
copy number of each antigen was then determined using the formula 2–ΔΔCt, with ΔΔCt = ΔCt 
(sample) – ΔCt (reference). The reference was a pool of RNA derived from three non-
neoplastic brain samples. Samples with at least a 5-fold increase in mRNA expression 
compared to the reference were considered as positive. 
 
Immunohistochemistry. 
  Immunohistochemistry was performed as described in (Saikali et al., 2007). Briefly, GBM 
sections from 20 GBM specimens unrelated to specimens used to generate GBM primary cell 
lines were deparaffinised and rehydrated in PBS, and then incubated for 30 min at 20°C with 
diluted primary antibodies against antigens (1/500, 1/50 and 1/100 dilutions for IDO, PDL-1 
and vimentin, respectively). An additional incubation was performed with an anti-mouse or 
goat antibody (DakoCytomation) for 30 min. Sections were revealed using the peroxidase 
substrate kit (Vector Laboratories, Vandoeuvre, France) and counterstained with hematoxylin. 
Microscopic analysis was performed using a Leitz-Diaplan microscope (Nuremburg, 
Germany). Results are expressed as the percentage of stained cells after counting 500 tumour 
cells in two different areas with the most intense expression, and represented as ‘–’ for no 
expression, ‘–/+’ for 1–25%; ‘+’ for 26–50%; ‘++’ for 51–75% and ‘+++’ for 76–100% of 
analysed cells. GBM samples with less than 26% of positive cells are arbitrarily considered as 
negative.  
 
Flow cytometry. 
  Cells were washed in PBS 2% FCS and incubated with saturating concentrations of 
unlabelled or fluorescent-labelled primary antibodies for 30 min at 4°C. An additional 
incubation with fluorescent-labelled secondary antibodies was performed when cells were 
stained with unlabelled primary antibodies. Cells were then washed with PBS 2% FCS and 
analysed by flow cytometry using a FACScan flow cytometer (BD Biosciences). For 
intracellular staining, cells were fixed with methanol and permeabilised with saponin. Data 
were then analysed with the CellQuest software (BD Biosciences). Results are expressed as 
specific fluorescence intensity given by the ratio of the geometric mean of test divided by the 
geometric mean of the isotype control.  
 
TGF-β2 secretion and IDO activity. 
  Cells were washed in culture medium and incubated for 48 hours at a concentration of 1x106 
cells per ml in the presence or not of 1000 U per ml of IFN-γ (Boehringer Ingelheim, Paris). 
Supernatants were then centrifuged at 400 g for 5 min and frozen at -20°C. IDO activity was 
evaluated by measuring tryptophan and kynurenin concentrations in culture supernatants by 
high performance liquid chromatography as described in (Widner et al., 1997). TGF-β2 
secretion was determined by ELISA following the manufacturer’s instructions (R&D 
Systems, Lille, France). Active form of TGF-β2 was analyzed after acidification of 
supernatants with HCl according to the manufacturer’s instructions.  
 
Generation of Melan-A/HLA-A2-specific CTLs. 
  HLA-A2 positive peripheral blood mononuclear cells (PBMC) from healthy donors were 
prepared as described in (Avril et al., 2009). Peripheral blood lymphocytes (PBL) and 
monocytes were separated by elutriation (J6-MC centrifuge, Beckman Coulter, Villepinte, 
France). Cells were then frozen in a 4% HSA (B Braun Medical SAS, Boulogne, France) 10% 
DMSO (LFB Biomedicaments, Courtaboeuf) solution. Melan-A/HLA-A2-specific CTLs were 
generated in vitro after repeated stimulations with autologous Melan-A peptide-pulsed 
dendritic cells.  
  To generate dendritic cells, monocytes were defrosted, washed and cultured for 6 days in 
RPMI 10% SVF supplemented with 1000 U per ml of rhGM-CSF (Novartis, Rueil-
Malmaison, France) and 200 U per ml of rhIL-4 (AbCys, Paris) at 37°C in a humidified 5% 
CO2 incubator. Before use, dendritic cells were matured overnight with 1000 U per ml of 
rhTNFα (CellGenix, Clermont l’Herault, France) and 50 µg per ml of Poly IC (Sigma). 
Mature dendritic cells were then harvested, resuspended in RPMI at 2x106 cells per ml and 
incubated with 10 µg per ml of Melan-A peptide (sequence: ELAGIGILTV, Genospheres 
Biotechnologies, Paris) for 1 hour at 37°C.  
  CD8+ T cell population was enriched from autologous PBL after depletion of CD4+ cells 
using a magnetic microbeads (Dynal, Invitrogen). Enriched CD8+ T cells (1x105 cells per 
well) were cocultured with Melan-A-pulsed dendritic cells (2x104 cells per well) in 200 µl of 
X-VIVO 15 medium (Lonza) supplemented with 5 ng per ml of rhIL-6 and rhIL-12 (Tébu-
Bio, Le Perray-en-Yvelines, France) in an 96U-well microplate. Lymphocytes were then 
restimulated once every week with freshly prepared autologous peptide-pulsed dendritic cells 
(1x104 cells per well), 20 U per ml of rhIL-2 (Novartis) and 5 ng per ml of rhIL-7 (Tébu-Bio). 
After 3 stimulations, cells expanded in each well were separately tested in a IFN-γ release 
assay using Melan-A-pulsed HLA-A2+ T2 cells as targets. Cells from positive wells were 
pooled and expanded with additional stimulations using autologous peptide-pulsed dendritic 
cells. Melan-A/HLA-A2-specific CTLs generated were finally tested by flow cytometry for 
their expression of CD3 and CD8 T cell markers and their binding of Melan-A/HLA-A2 
tetramer.  
 
IFN-γ release assay. 
  Irradiated target cells were washed and plated in RPMI 10% FCS at a concentration of 1x104 
per well in a 96U-well microplate. Effector cells were washed and added onto the target cells 
at 5x104 cells per well. Blocking antibodies (10µg per ml) and 1-methyltryptophane inhibitor 
(400 mM) were added 15 min before the effectors. Cells were then incubated for 24 hours at 
37°C at the final volume of 200 µl per well. At the end of the assay, 150 µl of supernatant 
were centrifuged and analysed for IFN-γ by ELISA, following the manufacturer’s instructions 
(Diaclone). 
 
Cytotoxicity assay. 
  5x106 target cells were labelled with 100 µCi of Na251CrO4 (GE Healthcare, Orsay, France) 
for 90 min at 37°C. Cells were washed twice in culture medium, resuspended in 1 ml of 
culture medium and incubated for 60 min at 37°C to allow spontaneous release of 51-
chromium. After 3 washes in culture medium, target cells were plated in X-VIVO medium at 
a concentration of 2x104 cells per well in a 96U-well microplate. Effector cells were washed 
in X-VIVO medium and added onto the target cells at different effector:target ratios as 
indicated in the figure 5. Blocking antibodies (10µg per ml) and 1-methyltryptophane 
inhibitor (400 mM) were added 15 min before the effectors and were present throughout the 
cytotoxicity assay. Cells were incubated for 4 or 24 hours at 37°C at the final volume of 200 
µl per well. Spontaneous and maximum releases were obtained by incubating target cells with 
the medium alone and with triton x-100, respectively. At the end of the assay, 50 µl of 
supernatant were transferred into a scintillation microplate (Lumaplate 96, Perkin Elmer, 
Courtaboeuf), dried overnight at 54°C and the radioactivity was measured with a gamma 
counter (TopCount, Packard Instruments, Meriden, United-States). The percentage of specific 
lysis was determined as followed: ((cpm of test release - cpm of spontaneous release) / (cpm 
of maximum release - cpm of spontaneous release)) * 100.  
 PHA-induced PBMC proliferation. 
  1x105 PBMC were cocultured with irradiated 2x104 tumour cells in the presence of 1 µg per 
ml of phytohemagglutinin (PHA) in a 96U-well microplate for 3 days at 37°C in a humidified 
5% CO2 incubator. For IDO inhibition, 1-methyl tryptophan inhibitor (400 mM) was added. 
3H thymidine (1 mCi/well; GE Healthcare) was added 18 hours before the end of the test. Cell 
incorporation of 3H thymidine was revealed by adding a scintillation fluid (Perkin Elmer) and 
measured with a gamma counter (Topcount).  
 
Statistics. 
  Values represent the mean ± standard deviation of n different experiments. The Student t-test 
is applied using a two-tailed distribution of two conditions of unequal or equal variances on 
groups of data obtained in the experiments. The significance level is p < 0.05. 
 
3. RESULTS 
 
FasL, HLA-G, IDO, PDL-1 and TGF-β1-3 mRNA expression in a series of GBM samples by 
expression microarray analysis. 
  We have recently reported a DNA target transcriptomic profiling on 20 GBM samples (de 
Tayrac et al., 2009). Using the complete microarray data set, FasL, HLA-G, IDO, PDL-1 and 
TGF-β1-3 transcripts expression was compared between GBM and non-tumour brain samples. 
A significant increase (expression fold change greater than two) is observed in 15%, 60%, 
85%, 30%, 70%, 80%, and 35% of GBM samples for FasL, HLA-G, IDO, PDL-1, TGF-β1, 
TGF-β2 and TGF-β3, respectively (Figure 1).  
 
FasL, HLA-G, IDO, PDL-1 and TGF-β1-3 mRNA expression in GBM cell lines. 
  For in vitro assays, we have generated 10 GBM primary cell lines, and used U251 and 
U87MG cell lines. GBM cell lines as well as U251 and U87MG cell lines were characterised 
by their expression of vimentin, an intermediate filament highly expressed in GBM cells 
(supplementary data, Figure S1A), as well as by their lack of expression of a neural marker 
TujIII, and an oligodendrocytic marker O4 (data not shown). All GBM cell lines also 
expressed at least one of the tumour antigens IL13Rα2, EGFRvIII or gp100 that we 
previously reported on GBM (Saikali et al., 2007) (supplementary data, Figure S1B).  
  We then used RT-PCR to test mRNA expression of FasL, HLA-G, IDO, PDL-1 and TGF-
β1-3 in GBM cell lines. Only 2 out of 10 GBM primary cell lines express FasL with a weak 
expression level compared to the positive control (Figure 2A). In addition, IFN-γ treatment 
was found to reduce the FasL mRNA expression of the positive cell lines. Consequently, this 
molecule was not studied further. HLA-G mRNA expression is not observed on GBM cell 
lines. Its expression is induced in only one out 10 GBM cell lines after IFN-γ treatment 
(Figure 2B). In contrast, most GBM primary cell lines express IDO, PDL-1 and TGF-β1-3 
mRNA at the resting state (Figure 2A) or after IFN-γ stimulation (Figure 2B). 
 
HLA class I, HLA-G and PDL-1 protein expression in GBM cell lines. 
  Protein expression of HLA-G and PDL-1 was screened by flow cytometry on both untreated 
and IFN-γ-treated GBM cell lines. As shown in Figure 3, the expression of MHC class I 
molecules is increased after IFN-γ treatment, demonstrating the efficiency of this treatment. 
In addition, expression of PDL-1 and HLA-G is observed in the positive controls IFN-γ-
treated monocytes and the JEG-3 trophoblastic cell line, respectively. However, none of the 
GBM cell lines express HLA-G even after IFN-γ stimulation. On the other hand, PDL-1 is 
expressed on most GBM cell lines (9 out of 10), while IFN-γ stimulation induces or increases 
the expression of this protein in all cell lines (Figure 3). 
 
IDO protein expression and activity in GBM cell lines. 
  The IDO protein expression was analysed by immunohistochemistry. Only a low proportion 
of untreated GBM cell lines express IDO (around 25% on average), except GBM#4 (around 
55%) (Figure 4A, Table 2), while the IDO expression increases in all GBM cell lines treated 
by IFN-γ. Interestingly, the immunostaining intensity is lower on untreated cells compared 
with IFN-γ-treated cells (Figure 4A). 
  The IDO activity in the supernatants of GBM cell lines was thereafter obtained by 
determining the level of tryptophan and kynurenin, this latter molecule being a degradation 
product of tryptophan. IDO activity is observed in half of the untreated GBM primary cell 
lines tested, being particularly high in GBM#4. IFN-γ stimulation induces or increases IDO 
activity in all the GBM cell lines (Figure 4B).  
 
TGF-β2 secretion by GBM cell lines. 
  TGF-β2 secretion is observed at various levels in the supernatants of 9 out of 10 untreated 
GBM cell lines (Figure 4C). Detection is observed only after acidification of the supernatants, 
suggesting that the latent form of TGF-β2 is mainly produced by GBM cell lines. 
Unexpectedly, IFN-γ treatment significantly reduces the secretion of TGF-β2. 
 
Melan-A/HLA-A2-specific T cell recognition of Melan-A-loaded GBM cell lines. 
  To test the involvement of IDO, PDL1 and TGF-β1-3 molecules in the sensibility of GBM 
cell lines to the effectors functions of T cells, we expanded antigen-specific T cell lines 
capable of recognizing GBM cell lines. Despite several attempts, we were unable to expand 
the IL13Rα2/HLA-A2-specific T cell lines as previously reported by Okano et al. (Okano et 
al., 2002). We therefore generated Melan-A/HLA-A2-specific T cell lines and tested them for 
Melan-A/HLA-A2 tetramer staining. As shown in Figure 5A, 80% of cells from T cell line 
cultures are CD8+ T cells which bind to the Melan-A/HLA-A2 tetramer. In addition, T cells 
secrete IFN-γ when they are cultivated in the presence of Melan-A-loaded T2 cells, which are 
used here as positive controls (Figure 5B). To test the recognition of GBM cell lines by these 
Melan-A/HLA-A2-specific T cell lines, GBM cells are unloaded or loaded with Melan-A 
peptides and cultivated with the T cell lines. Melan-A/HLA-A2-specific T cells are able to 
secrete IFN-γ when in the presence of Melan-A-loaded GBM primary cells, but not in the 
presence of unloaded GBM cells. Interestingly, a drastic reduction in T cell IFN-γ secretion is 
observed when Melan-A/HLA-A2-specific T cells are cultivated in the presence of Melan-A-
loaded GBM cells pre-treated by IFN-γ (Figure 5B). T cells lines were then used as cytotoxic 
effectors against unloaded or Melan-A-loaded T2 cells and GBM primary cells. As shown in 
Figure 5C, Melan-A/HLA-A2-specific T cells kill Melan-A-loaded T2 and GBM cells, but 
not unloaded cells. Again, T cell cytotoxicity is reduced against Melan-A-loaded GBM cells 
when they are pre-treated by IFN-γ.  
 
Role of IDO, PDL-1 and TGF-β1-3 on IFN-γ release and cell cytotoxicity of specific T cells. 
  Melan-A/HLA-A2-specific T cells were used as effectors in IFN-γ secretion and cell 
cytotoxicity assays against GBM cells in the presence of blocking antibodies against PDL-1 
or TGF-β1-3 and in the presence of 1-methyl-tryptophan, an inhibitor of the IDO enzyme. 
These reagents have neither effect on IFN-γ secretion nor cell cytotoxicity functions of 
Melan-A/HLA-A2-specific T cells against T2 cells (Figure 5D and 5E). By contrast, the 
presence of anti-PDL-1 antibodies increased the IFN-γ secretion of specific T cells in 
response to untreated or IFN-γ-pre-treated Melan-A-loaded GBM cells (Figure 5D) 
demonstrating the involvement of PDL-1 in the inhibition of T cell IFN-γ secretion. On the 
other hand, the inhibitors of TGF-β1-3 and IDO had no effect on IFN-γ secretion of specific T 
cells. None of the inhibitors tested have any effect as regards the cell cytotoxicity function, 
irrespective of whether the cytotoxicity assay lasted for 4 hours or 24 hours (Figure 5E and 
data not shown). Supernatants of untreated and IFN-γ-treated GBM cell lines were also tested 
for their ability to inhibit IFN-γ secretion of Melan-A-specific T cells in response to Melan-A 
loaded T2 cells. Only a modest inhibition (around 25%) was observed with untreated GBM 
supernatants but not with IFN-γ-treated GBM supernatants (supplementary data, Figure S2). 
Furthermore, this inhibition was abolished by anti-TGF-ß1-3 antibodies (see supplementary 
data, Figure S2). 
 
Role of IDO on PHA-induced PBMC proliferation. 
  IDO has been previously reported as being involved in the inhibition of lymphocyte 
proliferation. We tested the lectin-induced PBMC proliferation with GBM primary cell lines 
in the presence of the IDO inhibitor, 1-methyl-tryptophan. As expected, lectin PHA induces 
the proliferation of PBMC, and the presence of allogenic T2 cells enhances this effect (Figure 
6). In contrast, the PHA-induced proliferation of PBMC is reduced in the presence of GBM 
cells. Remarkably, this decrease is amplified when the GBM cells are pre-treated with IFN-γ 
(Figure 6). The use of 1-methyl-tryptophan partially restores the inhibition of PBMC 
proliferation, suggesting a direct anti-proliferating role of IDO on PBMC. 
 
IDO and PDL-1 mRNA and protein expressions in a series of 20 GBM samples. 
  To confirm the presence of IDO and PDL-1 molecules in vivo within the tumour, 20 
additional GBM samples were tested for mRNA expression of IDO and PDL-1 by Q-PCR and 
were immunohistochemically stained with anti-PDL-1 and IDO antibodies. mRNA expression 
was confirmed in 16 and 10 out of 20 GBM specimens for IDO (80%) and PDL-1 (50%) 
respectively (Figure 7A). Immunohistochemical expressions of PDL-1 and IDO were first 
confirmed in positive controls i.e. urothelial carcinoma and placenta samples, respectively. 
All of 20 GBM samples express IDO but only 45% express PDL-1 (Figure 7B, Table 3). A 
correlation between mRNA and protein expression was observed for PDL-1 but not for IDO 
(Figure 7C).  
 
4. DISCUSSION 
 
  In this study, we analyse the expression of five immunoregulatory molecules FasL, HLA-G, 
PDL-1, IDO and TGF-β1-3 in human GBM. Using GBM primary cell lines, we confirm the 
mRNA and protein expression of PDL-1, IDO and TGF-β2 molecules in most of the GBM 
cell lines. Furthermore, functional studies highlight the role of PDL-1, TGF-β1-3 and IDO in 
the inhibition of IFN-γ production by tumour-specific T cells and lectin-induced lymphocyte 
proliferation, respectively. None of these molecules are involved in the resistance of GBM to 
tumour-specific T cell cytotoxicity. 
 
  IFN-γ is a pleotropic cytokine that is generally undetectable within the central nervous 
system. Nevertheless, in response to brain infections or brain disorders such as multiple 
sclerosis, IFN-γ is produced locally in large amounts by reactive T cells, but also activated 
astrocytes and microglial cells (Popko et al., 1997), (Suzuki et al., 2005). Due to the 
inflammatory context induced by cancer, production of IFN-γ could be observed during 
tumoral processes in patients suffering from GBM. In addition, it has been shown that brain 
tumours and peritumoral regions express IFN-γ mRNA (Nitta et al., 1994). More recently, 
elevated IFN-γ serum concentrations have been reported in brain tumour patients compared to 
healthy donors (Mkhoyan et al., 2008). Considering these different points, we decided to 
investigate the immunoregulatory properties of resting or IFN-γ-treated GBM cells. 
 
  FasL and HLA-G expression has been previously reported in both GBM primary and 
immortalised cell lines as well as GBM specimens. FasL mRNA expression has been 
described by RT-PCR method in 6 out of 8 GBM immortalised cell lines and in 2 out of 6 
primary tumours (Gratas et al., 1997). The southern-blotting approach markedly increased the 
detection of positive samples (Gratas et al., 1997). The FasL protein was also present in most 
of the GBM specimens analysed by western-blotting (4 out of 5) (Saas et al., 1997), and 
immunohistochemistry (overall 58 out of 59) (Gratas et al., 1997), (Saas et al., 1997), (Strege 
et al., 2004). However, the expression level observed by flow cytometry within GBM primary 
cell lines was always very low (Saas et al., 1997), (Chahlavi et al., 2005). Using genomic 
microarray and conventional RT-PCR techniques, we only observe FasL mRNA expression 
in 3 out of 20 GBM specimens and in 2 out of 10 GBM primary cell lines. In addition, IFN-γ 
treatment diminishes significantly the FasL mRNA expression of the positive cell lines. For 
these reasons, the FasL molecule was not analysed further in our study. 
  HLA-G mRNA expression has been previously described within respectively 6 and 10 out 12 
untreated and IFN-γ-treated glioma immortalised cell lines (Wiendl et al., 2002). In the 
present study, none of the untreated GBM primary or immortalised cell lines express HLA-G 
mRNA, while its expression is observed in only one of the IFN-γ-treated GBM primary cell 
lines tested. This discrepancy might be due to the sensitivity of the methods used i.e. 
conventional RT-PCR in our study as against northern-blotting in (Wiendl et al., 2002). 
Differences in cell lines origin might also be incriminated: GBM primary cell lines versus 
glioma immortalised cell lines. In contrast to the lack of HLA-G mRNA expression in our 
GBM primary cell lines, 12 out of 20 GBM specimens tested expressed HLA-G mRNA 
according to our transcriptomic data. This could be due to the cell heterogeneity of the entire 
tumour used, which not only includes tumour cells, but also comprises a microenvironment 
compartment i.e. other locally recruited or infiltrated cells. It is now well known that cells 
from different origins can express HLA-G molecules (Amiot et al., 1998). Thus, we cannot 
rule out the possibility that these non-tumour cells contribute alone to the HLA-G expression 
detected by our transcriptomic microarray analysis. Using flow cytometry, we fail to detect 
any HLA-G protein expression on the cell surface of the GBM primary cell lines, as well as 
with U251 and U87 cells, even following treatment with IFN-γ. This is in agreement with the 
lack of HLA-G expression reported by a wide variety of solid tumours and especially in brain 
tumour specimens (Bainbridge et al., 2001), (Davies et al., 2001). Therefore, HLA-G was not 
taken into consideration in further functional assays.  
 
  Increased production of TGF-β1-3 occurs in various tumour types and correlates with 
tumour grade. (Bodmer et al., 1989), (Leitlein et al., 2001), (Pasche, 2001). TGF-β2 has been 
considered to play a crucial role in both malignant progression of glial tumours and immune 
dysfunction in human GBM patients (Weller and Fontana, 1995). Transcript and protein 
expression of TGF-β1-3 has long been known in malignant gliomas (Weller and Fontana, 
1995). In glioma cell lines, TGF-β1-3 were mainly documented in their small and large latent 
forms rather than their mature bioactive forms (Constam et al., 1992), (Olofsson et al., 1992). 
In the present study, we show that all untreated and IFN-γ-treated GBM cell lines express 
TGF-β2 transcripts. However, various levels of TGF-β2 secretion are observed between 
untreated GBM cell lines. This suggests that expression of TGF-β2 protein is finely regulated 
at the post- transcriptional level. Noticeably, the IFN-γ treatment decreases TGF-β2 secretion 
in all the GBM cell lines analysed. In addition, TGF-β2 from culture supernatants of GBM 
primary and immortalised cell lines can only be detected after acidification. This suggests that 
TGF-β2 is mostly secreted in its latent form. TGF-β1-3 have an important role in the 
regulation of anti-tumour immune responses, including the maturation of dendritic cells 
(Gorelik and Flavell, 2002) or the activation of T and NK cells (Thomas and Massagué, 
2005), (Eisele et al., 2006). TGF-β1 acts directly on CD8 T cell cytotoxicity by inhibiting the 
expression of FasL, perforin, granzymes A/B and IFN-γ genes (Thomas and Massagué, 2005). 
In this study, using blocking antibodies against TGF-β1-3, we fail to show any effect of TGF-
β1-3 in regulating T cell cytotoxicity against GBM primary cell lines. One plausible reason is 
that the latent or complex form of TGF-β2, the predominant isoform of TGF-β secreted by 
GBM cells (Leitlein et al., 2001), might not be cleaved during the 4-hour cytotoxicity assay, 
thus preventing its action on T cells. Indeed, the TGF-β1 effects on T cell cytotoxicity 
previously described in (Thomas and Massagué, 2005) can be obtained by pre-treating T cells 
typically for 24 hours before the cytotoxicity assay. Alternatively, in contrast to TGF-β1, 
TGF-β2 might have no direct effect on T cell cytotoxicity. Using Melan-A-loaded GBM cells 
as target cells, no inhibitory effect of TGF β1-3 is observed on IFN-γ secretion of Melan-A-
specific T cells. In contrast, supernatants of untreated GBM primary cell lines partially inhibit 
the IFN-γ secretion of specific T cells in response to Melan-A-loaded T2 target cells (see 
supplementary data, Figure S2); and this inhibition is completely reversed by anti-TGF-β1-3 
blocking antibodies. This suggests that at least a fraction of TGF-β1-3 is functional in this 
model and can inhibit T cell IFN-γ production. This discrepancy in the effect of TGF-β1-3 on 
T cell IFN-γ secretion might be due to the difference of concentration of TGF-β1-3 present in 
the two different models tested: the GBM cell concentration was 20 fold higher in 
experiments with supernatants. The mechanisms that regulate the activation of TGF-β1-3 are 
complex and not well fully understood. Small and large latent forms of TGF-β1-3 are 
converted to active forms of TGF-β1-3 by proteases such as metalloproteases of the 
extracellular matrix. Latent forms could also directly interact with cell surface receptors that 
change their conformation and release the activated TGF-β1-3 in an autocrine or a paracrine 
manner (Taylor, 2009). One could speculate that this phenomena is occurring in our IFN-γ 
secretion model. 
 
  In this work, we confirm the expression of IDO and PDL-1 in both GBM primary cell lines 
and tumour specimens at the mRNA and protein levels. PDL-1 expression was previously 
described in 12 untreated and IFN-γ-treated glioma immortalised cell lines (Wintterle et al., 
2003); 6 out of 7 GBM primary cell lines (Wilmotte et al., 2005) and in all of the 28 GBM 
specimens analysed (Wintterle et al., 2003), (Wilmotte et al., 2005). In this work, all untreated 
(except one) and IFN-γ-treated GBM cell lines express PDL-1 transcripts. However, variable 
protein expression levels are shown in the different untreated GBM cell lines. In addition, a 
correlation is observed in GBM specimens between mRNA level evaluated by Q-PCR and 
protein expression studied by immunohistochemistry. More than substantiating PDL-1 
expression in about half of the GBM specimens, with various proportions of positive tumour 
cells, this works highlights the functional role of PDL-1. This is the first study demonstrating 
that PDL-1 reduces IFN-γ production by T cells, in a tumour antigen-specific T cell model. 
This is in accordance with previous results obtained using allogenic CD4 and CD8 T cells 
(Wintterle et al., 2003) and superantigen-reactive T cells (Wilmotte et al., 2005).  
  Expression of the enzyme IDO has previously been shown in glioma immortalised cell lines 
(Grant and Kapoor, 2003), (Miyazaki et al., 2009) and GBM specimens (Uyttenhove et al., 
2003). We confirm mRNA and protein expression in both GBM primary cell lines and tumour 
specimens. As shown with other cell types in previous studies (Munn and Mellor, 2007), 
(Corm et al. 2009); differences between IDO mRNA, protein expression and IDO activity are 
observed in most of GBM cell lines. Using GBM specimens, a lack of correlation is also 
observed between mRNA expression detected by Q-PCR and protein expression detected by 
immunohistochemistry. This could be due to the heterogeneity of the tumour samples, but 
could also reflect the complex regulation of IDO gene, protein and enzymatic activity that is 
still not fully elucidated. In agreement with previous results obtained with immortalised GBM 
cell lines (Grant and Kapoor, 2003), (Miyazaki et al., 2009), we show that all the GBM cell 
lines treated with IFN-γ exhibit an IDO activity. Interestingly, IDO activity is also observed 
without any treatment in half of the cell lines. Moreover, the present study originally 
highlights the IDO functional role in GBM. Indeed, the IDO activity of GBM cell lines 
directly inhibits the lectin-dependent proliferation of human lymphocytes. Similar results have 
recently been described with ovarian cancer cells using an anti-CD3/28-induced T cell 
proliferation assay (Qian et al., 2009).  
 
  Concerning the functional assays with tumour-specific T cells, we first decided to use 
IL13Rα2 as a molecular target for GBM cells because this antigen is frequently expressed in 
GBM samples (Saikali et al., 2007). Indeed, we observed IL13Rα2 expression in all except 
one GBM primary cell line. Unfortunately, despite several attempts, we were unable to 
expand unmodified or modified IL13Rα2-specific T cells as previously described in (Okano 
et al., 2002), (Eguchi et al., 2006). Even though we could confirm the presence of a small 
fraction (around 20%) of IL13Rα2-specific T cells at the third stimulation by tetramer 
staining, all of T cells died subsequently to additional stimulations (data not shown). 
Recently, Zhang et al. have reported the expression of MART-1/Melan-A antigen in glioma 
immortalised cell lines such as U251 and U87MG and pointed out that the fact that Melan-A-
specific T cell clones could recognize and kill of these cells (Zhang et al., 2007). In our 
laboratory, Melan-A-specific T cell lines were generated and tested for IFN-γ production and 
cytotoxic activity in response to HLA-A2-positive GBM primary and U251 cell lines. 
Surprisingly, we are only able to show IFN-γ production or cytotoxic responses occurred only 
when target cells are loaded with Melan-A peptides, suggesting that GBM cells do not 
efficiently present Melan-A peptides on their surface. This suggests that GBM does not 
express MART-1 antigen. Indeed, Zhang et al. have show that only 4 out of 25 GBM 
specimens express Melan-A mRNA by quantitative PCR and microarray analyses (Zhang et 
al., 2007). Furthermore, in our laboratory, we fail to observe the Melan-A expression in a 
series of 34 GBM samples by quantitative RT-PCR (data not shown).  
  Using Melan-A-loaded GBM cell lines as target cells, we show that Melan-A-specific T cell 
lines recognize these target cells and, in response, produce IFN-γ and thus kill the cells. 
However, the pre-treatment of GBM cells with IFN-γ reduces markedly the IFN-γ secretion 
and decreases the cytotoxicity activity of specific T cells, whereas it increases the expression 
of HLA class I molecules, which are the molecular targets for T cell recognition. We can 
speculate that novel immunoregulatory molecules might be induced by IFN-γ and thus inhibit 
T cell functions. We demonstrate that PDL-1 is, at least in part, involved in the inhibition of T 
cell IFN-γ production. However, none of the molecules PDL-1, IDO and TGF-β1-3 have any 
direct role in inhibiting the T cell cytotoxic function. Identification of the molecules involved 
in this process is currently under investigation in our laboratory. In vivo, we should expect 
tumour resistance to T cell mediated responses to be finely regulated in GBM patients. On the 
one hand, tumour infiltrating T cells would locally produce IFN-γ that could directly act on 
tumour cells by over-expressing molecules such as HLA class I molecules, which would 
therefore increase the tumour recognition by other T cells. On the other hand, IFN-γ-exposed 
tumour cells would up-regulate molecules such as PDL-1 and IDO that inhibit T cell 
functions. As a result, tumour cells would adapt and reinforce their resistance to T cell 
responses. 
 
  Immunotherapy is a promising new approach to cure GBM patients (Yamanaka, 2008). It is 
noteworthy that patients treated with dendritic cell vaccinations have demonstrated intra-
tumour infiltration of cytotoxic T cells (Yamanaka et al., 2003), (Kikuchi et al., 2004), (Yu et 
al., 2004). However, as we show here, we should not underestimate the immunosuppressive 
properties of the tumour, which involve molecules such as PDL-1, IDO and TGF-β2. This 
suggests that the immunotherapy approach has to be multimodal and should combine 
activators of immune cell effectors and inhibitors that counteract the immunosuppressive 
activities of the tumour. Novel inhibitors of IDO, PDL-1 and TGF-β2 have been recently 
developed and are currently investigated in phase I/II clinical trials. The novel IDO enzyme 
inhibitor 1MT has recently been used in a phase I study in refractory solid malignancies 
(Soliman et al., 2009). Both the safety and efficiency of this treatment have been 
demonstrated, and future trials will combine 1-MT with other immunotherapies and 
chemotherapies in solid tumours. In addition, two antibodies CT-011 and MDX-1106 against 
PD-1, that block its interaction with the ligands PDL-1 and -2, have been recently developed 
and are currently used in phase II clinical trials in advanced hematological malignancies 
(Berger et al., 2008), as well as refractory or relapsed solid tumours of lung, kidney, colon 
skin and prostate (Brahmer et al., 2009). In summarize, it is hoped that the development of 
such molecules will provide essential adjuvants that will improve the efficiency of GBM 
patients treatment by immunotherapy involving T cell responses.  
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Table 1: Primers used in the RT-PCR experiments* 
 
 
  Target Primer sequence Expected size of the 
   gene   PCR-amplified fragment 
 
 
  β-actin  S: 5’-AGAGATGGCCACGGCTGCTT-3’ 653 bp 
 AS: 5’-ATTTGCGGTGGACGATGGAG-3’ 
  FasL S: 5’-GTGCCCAGAAGGCCTGGTCAAAGG-3’ 503 bp 
 AS: 5’-TTGCAAGATTGACCCCGGAAGTAT-3’ 
  HLA-G S: 5’-CGGAGTATTGGGAAGAGGAG-3’ 722 bp for HLA-G1 
 AS: 5’-TACAGCTGCAAGGACAACCA-3’ 446 bp for HLA-G2 and -G4 
  170 bp for HLA-G3 
  844 bp for HLA-G5 
  568 bp for HLA-G6 
 
  IDO S: 5’-ACAGACCACAAGTCACAGCG-3’ 662 bp 
 AS: 5’-AACTGAGCAGCATGTCCTCC-3’ 
  PDL-1 S: 5’-GACCTATATGTGGTAGAGTATGGTAGC-3’ 594 bp 
 AS: 5’-TTCAGCTGTATGGTTTTCCTCAGGATC-3’ 
  TGF-β1 S: 5’-GCGGTACCTGAACCCGTGTT-3’ 477 bp 
 AS: 5’-GTCAATGTACAGCTGCCGCAC-3’ 
  TGF-β2 S: 5’-CCGGAGGTGATTTCCATCTA-3’ 219 bp 
 AS: 5’-CTCCATTGCTGAGACGTCAA-3’ 
  TGF-β3 S: 5’-CTCTCTGTCCACTTGCACCA-3’ 344 bp 
 AS: 5’-ACACATTGAAGCGGAAAACC-3’ 
 
 
* S: sense primer; AS: anti-sense primer. 
Table 2: IDO protein expression on GBM cell lines* 
 
 
   GBM cell lines untreated IFN-γ-treated 
 
 
GBM #1   + +++ 
GBM #2  -/+ +++ 
GBM #3   + +++ 
GBM #4  ++ +++ 
GBM #5   + +++ 
GBM #6   + +++ 
GBM #7  -/+ +++ 
GBM #8   + +++ 
GBM #9  -/+ +++ 
GBM #10  -/+ +++ 
U251  -/+ +++ 
U87MG  -/+ +++ 
 
 
* Protein expression was analysed by immunohistochemistry 
on 10 GBM primary cell lines, U251 and U87MG after staining 
with specific antibodies against IDO. Results are expressed 
as percentage of positive tumour cells, as described in 
Materials and Methods. -: negative; -/+: 1–25%; +: 26–50%; 
++: 51–75%; and +++: 76–100% of analysed cells. 
 
 
 
Table 3: IDO and PDL-1 protein expression on GBM specimens* 
 
 
   GBM  IDO PDL-1 
 samples staining  staining 
 
 
#1 +++  ++ 
#2 +++ +++ 
#3  ++  -/+ 
#4 +++   + 
#5 +++  -/+ 
#6  ++  -/+ 
#7 +++  -/+ 
#8  ++  -/+ 
#9 +++  -/+ 
#10 +++  -/+ 
#11 +++  -/+ 
#12 +++ +++ 
#13 +++ +++ 
#14 +++  -/+ 
#15 +++   + 
#16  ++  -/+ 
#17 +++   + 
#18 +++   + 
#19  ++  -/+ 
#20 +++   + 
 
 
* Protein expression was analysed by 
immunohistochemistry on 20 GBM samples after 
staining of the tumour sections with specific 
antibodies against IDO and PDL-1. GBM 
specimens are unrelated to specimens used to 
generate GBM primary cell lines. Results are 
expressed as percentage of positive tumour cells 
as described in Materials and Methods. -: negative; 
-/+: 1–25%; +: 26–50%; ++: 51–75%; and +++: 76–
100% of analysed cells. 
 
 
 FIGURE LEGENDS 
 
Figure 1: FasL, HLA-G, IDO, PDL-1 and TGF-β1-3 mRNA expression on 20 GBM samples 
by transcriptomic microarray analysis. 
  Total mRNA from 20 GBM samples was extracted and analysed for a gene expression 
profile as described in (de Tayrac et al., 2009). Results are expressed as the relative mRNA 
expression compared to a pool of non-neoplastic brain samples. Samples are considered as 
positive when relative mRNA expression shows more than a two-fold increase (solid line) 
compared to the reference. 
 
 
Figure 2: FasL, HLA-G, IDO, PDL-1 and TGF-β1-3 mRNA expression on GBM cell lines by 
RT-PCR. 
  Total mRNA from untreated (A) or IFN-γ-treated (B) GBM primary cell lines, U251 and 
U87MG was extracted, reverse transcribed and then amplified with specific primers for β-
actin, FasL, HLA-G, IDO, PDL-1 and TGF-β1-3 molecules. Positive controls were used: 
JURKAT cell line for FasL and β-actin, JEG-3 cell line for HLA-G, IFN-γ-treated monocytes 
for IDO and PDL-1, and MCF-7 cell line for TGF-β1-3. Amplified products were analysed by 
electrophoresis in 2% agarose gel and migrated at the position corresponding to their expected 
size.  
 
 
Figure 3: HLA class I, HLA-G and PDL-1 protein expression on GBM cell lines. 
  Untreated (shaded histograms) or IFN-γ-treated GBM  cell lines, U251 and U87MG (open 
histograms with thick lines) were stained with isotype controls (open histograms with thin 
lines) or specific labelled antibodies against HLA class I, HLA-G and PDL-1 molecules, and 
then analysed by flow cytometry. JEG-3 cell line and IFN-γ-treated monocytes were used as 
positive controls for HLA-G and PDL-1 expression, respectively. Values in the top-right 
corners (in bold for IFN-γ-treated cells) indicate the mean of specific fluorescence intensity of 
the protein expression determined in at less three different experiments as described in 
Materials and Methods.  
 
 
Figure 4: IDO protein expression, IDO activity and TGF-β2 secretion on GBM cell lines. 
  (A): Untreated or IFN-γ-treated GBM cell lines were stained with specific anti-IDO 
antibodies and analysed by immunohistochemistry as described in Materials and Methods. 
Sections of human placenta, as positive controls, were stained with an isotype control and 
anti-IDO antibodies. A representative primary cell line GBM#2 is shown. (B and C): 
Untreated (□) or IFN-γ-treated (■) GBM cell lines, U251 and U87MG were cultured for 48 
hours in fresh medium. Supernatants were then collected and analysed for IDO activity (B) 
and TGF-β2 secretion (C). Levels of tryptophan and kynurenin were assessed by HPLC and 
IDO activity was determined by the ratio kynurenin / tryptophan. Supernatants of untreated 
and IFN-γ-treated monocytes were used as controls (B). TGF-β2 secretion was performed by 
ELISA after acidification of the supernatants (C). Results are representative of results 
obtained in three independent experiments. 
 
 
Figure 5: Role of IDO, PDL-1 and TGF-β1-3 on IFN-γ production and cell cytotoxicity of 
Melan-A/HLA-A2-specific T cells against Melan-A-loaded GBM cell lines. 
  Melan-A/HLA-A2-specific T cell lines were generated in vitro after co-culture with 
autologous dendritic cells loaded with Melan-A peptides. (A): Melan-A/HLA-A2-specific T 
cell lines obtained were stained with Melan-A/HLA-A2 tetramers and anti-CD8 antibodies, 
and then analysed by flow cytometry. (B): Melan-A/HLA-A2-specific T cell lines were 
incubated with unloaded or Melan-A-loaded HLA-A2 expressing T2 cells (used as controls) 
and untreated (□) or IFN-γ-treated (■) GBM cell lines for 24 hours. Supernatants were then 
collected and analysed for IFN-γ production by ELISA. (C): Melan-A/HLA-A2-specific T 
cell lines were used as effectors in a 4 hours cell cytotoxicity assay against 51Cr-labelled 
unloaded (■) or Melan-A-loaded (□) T2 cells, untreated (□) and IFN-γ-treated (■) GBM cell 
lines. Different effector : target (E:T) ratios were used and specific lysis was calculated as 
indicated in Materials and Methods. Melan-A/HLA-A2-specific T cell lines were used as 
effectors in a 24-hr IFN-γ production (D) and 4-hr cell cytotoxicity assays (E) in the presence 
or not (□) of blocking antibodies against PDL-1 (■); TGF-β1-3 (■) or in the presence of 1-
methyl tryptophan (■), an IDO inhibitor. Melan-A-loaded T2, untreated and IFN-γ-treated 
GBM cell lines were used as target cells. Results are representative of results obtained with 
three different Melan-A/HLA-A2-specific T cell lines. (*) p<0.05. 
 
 
Figure 6: Role of IDO on PHA-induced PBMC proliferation. 
  PBMC were cultured for 3 days with PHA and irradiated T2 cells (used as a control), 
untreated or IFN-γ-treated GBM cell lines in the presence or not (□) of 1-methyl tryptophan 
(■). 3H-thymidine was added 18 hours before the end of the assay and cell incorporation of 
3H-thymidine, corresponding to the PBMC proliferation, was determined as described in 
Materials and Methods. (*) p<0.05. 
  
Figure 7: IDO and PDL-1 mRNA and protein expression in a series of 20 GBM samples. 
  (A): mRNA from a series of 20 GBM specimens was isolated and analysed by Q-PCR for 
IDO and PDL-1 mRNA expression. Results are expressed as the relative mRNA expression 
compared to a pool of non-neoplastic brain samples. The solid line indicates the 5-fold 
increase in mRNA expression compared to the reference. (B): GBM samples were stained 
with specific anti-IDO or anti-PDL-1 antibodies and analysed by immunohistochemistry. 
Placenta and urothelial carcinoma sections were used as positive controls for IDO and PDL-1, 
respectively. Two representative GBM specimens are shown. (C): The correlation curves 
between RNA expression and protein expression are calculated for IDO and PDL-1 
molecules. R2 indicates the correlation coefficient. 
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Materials and methods 
 
GBM cell lines supernatants. 
  Cells were grown in culture medium for 48 hours in the presence or not of 1000 U per ml of 
IFN-γ. Cells were then washed and incubated in culture medium for 24 hours at a 
concentration of 1x106 cells per ml. Supernatants were then centrifuged at 400 g for 5 min and 
used in the IFN-γ release assay. For blocking experiments, supernatants were incubated with 
antibodies against PDL-1 and TGF-β1-3 (10µg per ml) for 18 hours at 4°C before used in the 
IFN-γ secretion assay. 
 
IFN-γ release assay. 
  Irradiated HLA-A2 expressing T2 target cells were washed and plated in RPMI 10% FCS at 
a concentration of 1x104 per well in a 96U-well microplate. Melan-A/HLA-A2-specific T cell 
lines used as effector cells were washed and added to the target cells at 5x104 cells per well. 
Supernatants obtained from untreated or IFN-γ-treated GBM cell lines were added at 3:4 
dilution. Cells were incubated for 24 hours at 37°C at the final volume of 200 µl per well. At 
the end of the assay, 150 µl of supernatant were centrifuged and analysed for IFN-γ by 
ELISA. 
 
 
 
 
 
 
 
 
Figure legends 
 
Figure S1: Expression of vimentin and tumour antigens by GBM primary cell lines. 
  10 GBM primary cell lines were generated from GBM samples and characterised by their 
expression of vimentin (A) and tumour antigens IL13Rα2, EGFRvIII and gp100 (B). 
Vimentin expression was performed by immunohistochemistry. Tumour antigen expression 
was analysed by flow cytometry after staining with specific labelled antibodies. For gp100 
expression, cells were fixed and permeabilised before the staining. Values in the top-right 
corners indicate the mean of specific fluorescence intensity of the tumour antigens tested 
determined in at less three different experiments as described in Materials and Methods. GBM 
cell lines were considered as positive when the specific fluorescence intensity was more than 
two. 
 
Figure S2: Role of PDL-1 and TGF-β1-3 on IFN-γ production of Melan-A/HLA-A2-specific T 
cells against Melan-A-loaded T2 cell lines in the presence of untreated or IFN-γ-treated GBM 
cell lines supernatants. 
  Melan-A/HLA-A2-specific T cell lines were incubated with unloaded or Melan-A-loaded 
HLA-A2 expressing T2 cells for 24 hours in the presence of supernatants obtained from 
untreated or IFN-γ-treated GBM cell lines (□). Blocking antibodies against PDL-1 (■); TGF-
β1-3 (■) were added 18 hours to the supernatants and left during the assay. (**) p<0.01. 
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